Table: q1_q4_2020_prescription_drugs_wac_increases , manufacturer_name like T*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2020	64764030020	Entyvio 300mg 20mL Vial	01/03/2020	258.75	6727.65	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	12/31/2020	64764030020	Entyvio 300mg 20mL Vial	10/19/2020	269.11	6996.76	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in the last 5 years. Please note that Patent Expiration Date is not publicly available for Entyvio. For more information about Takeda’s approach to pricing medicines in the U.S., please refer to Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2020	64764073030	Trintellix 10mg 30ct Tablet	01/03/2020	19.18	402.85	03/21/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2020	64764075030	Trintellix 20mg 30ct Tablet	01/03/2020	19.18	402.85	03/21/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000105	Takeda Pharmaceuticals America, Inc.	03/31/2020	64764072030	Trintellix 5mg 30ct Tablet	01/03/2020	19.18	402.85	03/21/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Not acquired in last 5 years; Takeda’s approach to pricing medicines in the U.S. reflects our strong commitment to bringing the right treatment options to patients who may benefit from them. Please see Takeda's US Pricing Philosophy at: https://www.takeda.com/en-us/corporate-responsibility/takeda-pricing-philosophy/
Rx0000232	TerSera Therapeutics LLC	06/30/2020	70720072010	Prialt Intrathecal Solution 100 MCG/ML, 1ML Vial, Qty 1	06/29/2020	53.95	883.95	10/01/2024	Single Source Drug	None	1	None	1	None	1	09/27/2018	Jazz Pharmaceuticals, Inc.	80000000	None	None	744.98	716.05	2004	608.33	None	TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. Note: per MediSpan there may be only one price increase listed for this Prialt product - note that our Five-Year History includes price increase information prior to TerSera's acquisition of Prialt, at which time TerSera acquired new NDC numbers for the Prialt line of products.
Rx0000232	TerSera Therapeutics LLC	06/30/2020	70720072210	Prialt Intrathecal Solution 100 MCG/ML, 5ML Vial, Qty 1	06/29/2020	207.50	4357.50	10/01/2024	Single Source Drug	None	1	None	1	None	1	09/27/2018	Jazz Pharmaceuticals, Inc.	80000000	None	None	3724.90	3580.25	2004	3041.67	None	TerSera NDC first launched on 12/02/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. Note: per MediSpan there may be only one price increase listed for this Prialt product - note that our Five-Year History includes price increase information prior to TerSera's acquisition of Prialt, at which time TerSera acquired new NDC numbers for the Prialt line of products.
Rx0000232	TerSera Therapeutics LLC	06/30/2020	70720072310	Prialt Intrathecal Solution 25 MCG/ML, 20ML Vial, Qty 1	06/29/2020	207.50	4357.50	10/01/2024	Single Source Drug	None	1	None	1	None	1	09/27/2018	Jazz Pharmaceuticals, Inc.	80000000	None	None	3724.90	3580.25	2004	3041.67	None	TerSera NDC first launched on 10/09/2019. Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available. Note: per MediSpan there may be only one price increase listed for this Prialt product - note that our Five-Year History includes price increase information prior to TerSera's acquisition of Prialt, at which time TerSera acquired new NDC numbers for the Prialt line of products.
Rx0000232	TerSera Therapeutics LLC	12/31/2020	70183012584	XERMELO (telostristat ethyl), Oral Tablet, 250mg, 1 Case/84 Tablets	11/09/2020	649.34	7208.34	02/27/2031	Single Source Drug	None	1	TerSera's pricing is determined after careful consideration of several factors, including funding research and development, product affordability, providing patient assistance programs for patients in need, competitor pricing, and dynamic reimbursement rates.	None	No Change	None	09/08/2020	Lexicon Pharmaceuticals, Inc.	160000000	None	Lexicon received approximately $160M in upfront payments and up to $65 million in future milestone payments plus mid-teens royalties on net sales of XERMELO for the treatment of biliary tract cancer.	6559.00	5961.00	2017	5164.00	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which TerSera believes is in the public domain or otherwise publicly available.
Rx0000217	Teva Neuroscience, Inc.	03/31/2020	68546017260	AUSTEDO TABLETS 12MG 60	01/01/2020	323.30	5802.20	03/27/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC’s subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.”
Rx0000217	Teva Neuroscience, Inc.	03/31/2020	68546017060	AUSTEDO TABLETS 6MG 60	01/01/2020	215.50	3868.10	03/27/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC’s subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.”
Rx0000217	Teva Neuroscience, Inc.	03/31/2020	68546017160	AUSTEDO TABLETS 9MG 60	01/01/2020	242.40	4351.60	03/27/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC’s subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.”
Rx0000217	Teva Neuroscience, Inc.	03/31/2020	68546014256	AZILECT TABLETS 0.5MG 30	01/01/2020	50.10	832.60	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000217	Teva Neuroscience, Inc.	03/31/2020	68546022956	AZILECT TABLETS 1MG 30	01/01/2020	50.10	832.60	08/27/2027	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459051230	ACTIQ BKU 1200MCG 1CTNX30 US	01/01/2020	314.40	5227.40	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459051630	ACTIQ BKU 1600MCG 1CTNX30 US	01/01/2020	387.90	6448.70	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459050230	ACTIQ BKU 200MCG 1CTNX30 US	01/01/2020	131.80	2190.40	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459050430	ACTIQ BKU 400MCG 1CTNX30 US	01/01/2020	166.80	2772.30	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459050630	ACTIQ BKU 600MCG 1CTNX30 US	01/01/2020	204.40	3397.60	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459050830	ACTIQ BKU 800MCG 1CTNX30 US	01/01/2020	241.90	4021.60	09/05/2006	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844011001	ADDERALL(R) TABLETS 10MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844011201	ADDERALL(R) TABLETS 12.5MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844011501	ADDERALL(R) TABLETS 15MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844012001	ADDERALL(R) TABLETS 20MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844013001	ADDERALL(R) TABLETS 30MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844010501	ADDERALL(R) TABLETS 5MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844011701	ADDERALL(R) TABLETS 7.5MG 100	01/01/2020	45.00	748.60	01/06/2021	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459070060	AMRIX CAP 15 MG 1BT X60	01/01/2020	152.50	2535.50	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459070160	AMRIX CAP 30 MG 1BTLX60	01/01/2020	152.50	2535.50	02/26/2025	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459054128	FENTORA TB 100MCG 1CTNX28 US	01/01/2020	96.40	1603.30	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459054228	FENTORA TB 200MCG 1CTNX28 US	01/01/2020	121.80	2025.70	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459054428	FENTORA TB 400MCG 1CTNX28 US	01/01/2020	176.80	2939.20	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459054628	FENTORA TB 600MCG 1CTNX28 US	01/01/2020	229.50	3815.90	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459054828	FENTORA TB 800MCG 1CTNX28 US	01/01/2020	282.80	4701.10	06/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	52544008001	FIORICET 50/300/40MG CAPSULES 100	01/01/2020	32.80	544.80	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	08/02/2016	Watson/Actavis	None	1	"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price."	449.93	None	2013	227.00	None	"No patent expiration date listed - no patents ever listed"
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	52544008201	FIORICET/CODEINE 50/300/40/30MG CAPS 100	01/01/2020	68.60	1140.50	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	08/02/2016	Watson/Actavis	None	1	"Teva acquired this particular molecule/product as part of a broader deal involving other assets, and its acquisition price was incorporated into that deal’s overall purchase price."	942.09	None	2013	475.00	None	"No patent expiration date listed - no patents ever listed"
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459041230	GABITRIL TAB 12MG 1BTLX30	01/01/2020	23.20	385.90	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459041630	GABITRIL TAB 16MG 1BTLX30	01/01/2020	30.40	505.30	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459040230	GABITRIL TAB 2MG 1BTLX30	01/01/2020	18.00	298.50	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459040430	GABITRIL TAB 4MG 1BTLX30	01/01/2020	18.00	298.50	06/10/2017	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844021552	GALZIN CAPSULES 25MG 250	01/01/2020	26.10	433.40	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	57844020852	GALZIN CAPSULES 50MG 250	01/01/2020	43.40	722.20	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459021530	NUVIGIL TAB 150MG 1BTLX30	01/01/2020	50.90	846.80	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459022030	NUVIGIL TAB 200MG 1BTLX30	01/01/2020	50.90	846.80	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459022530	NUVIGIL TAB 250MG 1BTLX30	01/01/2020	50.90	846.80	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459020530	NUVIGIL TAB 50MG 1BTLX30	01/01/2020	16.90	281.40	06/18/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	00575620030	PROGLYCEM ORAL SUSPENSION 50MG/ML 30ML	01/01/2020	20.70	344.40	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; CMS Market Date is defaulted to 1990."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459010130	PROVIGIL TAB 100MG 1BTLX30	01/01/2020	71.30	1185.00	05/29/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459020130	PROVIGIL TAB 200MG 1BTLX30	01/01/2020	107.70	1790.50	05/29/2024	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000019	Teva Pharmaceuticals USA	03/31/2020	63459017714	SYNRIBO INJECTION 3.5 MG VIAL	01/01/2020	66.90	1112.00	10/26/2026	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310057922	PROAIR INH AERO 90MCG 1INH 200/ACT	01/01/2020	1.95	66.88	05/18/2031	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.”
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310058020	PROAIR RESPICLICK 200 DOSE-117UG	01/01/2020	1.82	62.52	08/28/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Launched NDC subsequent to acquiring molecule, which was in development (but not yet on market) at time of acquisition. The drug was not acquired within the last 5 years.”
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310021012	QNASL AERO 80MCG 8.7GM 120/SPRAY	01/01/2020	14.63	243.18	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310040606	QNASL PLV INHALER 40MCG 60/ACT TRADE	01/01/2020	14.63	243.18	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310041012	QNASL PLV INHALER 80MCG 120/ACT TRADE	01/01/2020	14.63	243.18	10/21/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310030240	QVAR BA INHALER 40MCG 120/ACT TRADE	01/01/2020	10.77	190.21	01/01/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years. This drug was initially published in the Pricing Compendia, with a WAC of $156.74, in December 2017 (before its launch). The drug was then launched, on February 12, 2018, with a WAC of $169.28, and the price was adjusted to $179.44– the first WAC increase taken following the product’s launch – on 1/1/2019."
Rx0000218	Teva Respiratory, LLC	03/31/2020	59310030480	QVAR BA INHALER 80MCG 120/ACT TRADE	01/01/2020	14.42	254.68	01/01/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years. This drug was initially published in the Pricing Compendia, with a WAC of $209.87, in December 2017 (before its launch). The drug was then launched, on February 12, 2018, with a WAC of $226.66, and the price was adjusted to $240.26 – the first WAC increase taken following the product’s launch – on 1/1/2019."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285052302	ANTABUSE TABLETS 250MG 100	01/01/2020	52.80	877.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285052402	ANTABUSE TABLETS 500MG 100	01/01/2020	84.40	1403.30	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285042410	AYGESTIN(R) TABLETS 5MG 50	01/01/2020	15.20	253.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed; The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285013197	LOESTRIN (R) 21 TABLETS 1.0MG/20MCG 105	01/01/2020	42.30	703.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285012797	LOESTRIN (R) 21 TABLETS 1.5MG/30MCG 105	01/01/2020	42.30	703.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285012570	LOESTRIN (R) FE 28 TAB 1MG/20MCG 140	01/01/2020	42.30	703.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285012870	LOESTRIN (R) FE 28 TABLETS 1.5MG/30MCG 140	01/01/2020	42.30	703.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. Teva developed and launched the drug."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285009287	LOSEASONIQUE™ TAB 182	01/01/2020	49.20	818.20	12/05/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285012058	MIRCETTE 28 TABLETS .15MG/.02MG .01MG	01/01/2020	53.00	881.50	10/20/2008	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"Teva developed and launched the drug."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285006390	PREFEST(R) TABLETS 180	01/01/2020	54.00	898.00	03/20/2020	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285043187	QUARTETTE (TM) TAB 182	01/01/2020	58.90	979.80	03/11/2029	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285008787	SEASONIQUE(TM) TAB 182	01/01/2020	49.20	818.20	12/05/2028	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285036801	TREXALL(R) (METHOTREXATE TAB, USP 10MG)	01/01/2020	58.10	966.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285036901	TREXALL(R) (METHOTREXATE TAB, USP 15MG)	01/01/2020	87.20	1449.20	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285036601	TREXALL(R) (METHOTREXATE TAB, USP 5MG)	01/01/2020	29.10	483.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285036701	TREXALL(R) (METHOTREXATE TAB, USP 7.5MG)	01/01/2020	43.60	724.60	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"No patent expiration date listed - no patents ever listed. The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285004001	ZIAC(R) TABLETS 10MG/6.25MG 30	01/01/2020	12.40	206.40	03/24/2000	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285004702	ZIAC(R) TABLETS 2.5MG/6.25MG 100	01/01/2020	41.40	687.80	03/24/2000	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000219	Teva Women's Health, Inc.	03/31/2020	51285005002	ZIAC(R) TABLETS 5MG/6.25MG 100	01/01/2020	41.40	687.80	03/24/2000	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	"The drug was not acquired within the last 5 years."
Rx0000183	Tris Pharma, Inc	03/31/2020	24478032204	Quillivant XR (methylphenidate hydrochloride) 300 mg/120 mL	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	64913	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	None
Rx0000183	Tris Pharma, Inc	03/31/2020	24478020020	Quillivant XR (methylphenidate hydrochloride) 300 mg/120 mL - PFE	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	841	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution.
Rx0000183	Tris Pharma, Inc	03/31/2020	24478032102	Quillivant XR (methylphenidate hydrochloride) 300 mg/60 mL	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	25285	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	None
Rx0000183	Tris Pharma, Inc	03/31/2020	24478019010	Quillivant XR (methylphenidate hydrochloride) 300 mg/60 mL - PFE	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	218	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution.
Rx0000183	Tris Pharma, Inc	03/31/2020	24478032305	Quillivant XR (methylphenidate hydrochloride) 750 mg/150 mL	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	36556	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	None
Rx0000183	Tris Pharma, Inc	03/31/2020	24478020525	Quillivant XR (methylphenidate hydrochloride) 750 mg/150 mL - PFE	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	866	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution.
Rx0000183	Tris Pharma, Inc	03/31/2020	24478032406	Quillivant XR (methylphenidate hydrochloride) 900 mg/180 mL	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	50008	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	None
Rx0000183	Tris Pharma, Inc	03/31/2020	24478021030	Quillivant XR (methylphenidate hydrochloride) 900 mg/180 mL - PFE	01/06/2020	27.97	310.47	02/15/2031	Single Source Drug	1128	None	Increased operational costs associated with product acquisition in 2018.	None	N/A	None	09/21/2018	Pfizer	None	1	Acquisition price also included another product not required for this report - Quillichew ER.	282.50	272.70	2015	192.94	None	Pfizer NDC numbers, 24478019010, 24478020020, 24478020525 and 24478021030 discontinued after acquisition in 2018. 2019 unit volume represents remainder in distribution.